Covance CVD

  1. All
  2. Commentary
  3. Headlines
    1. Charles Rivers Posts Strong 2Q Results as Early Stage Demand Finally Returns

      Commentary

      Thu, 7 Aug 2014

      year. We believe this segment is the best comparison to Covance 's early-stage business, and Charles River’s performance compares favorably to Covance 's early-stage reported revenue of 7.7%. While Charles

    2. Quintiles Posts Solid 2Q, Weak Bookings Unlikely to Be a Cause for Concern

      Commentary

      Thu, 31 Jul 2014

      rather than a more concerning slowdown in demand. Based on the strong book/bill ratios we have seen out of its peers Covance and ICON, which have already reported this quarter, we are inclined to agree with management. The firm's less attractive

    3. Covance Posts Light Results Relative to Peers, but Still on Track to Meet Full-Year Estimates

      Commentary

      Fri, 2 May 2014

      Covance reported first-quarter results that slightly ..... industrywide overcapacity and weak demand, but Covance has shown signs of improvement. The segment has ..... however, it was boosted by 10.9% growth in Covance ’s large central lab business. The clinical

    4. Covance beats by $0.01, misses on revenue

      Headlines

      Thu, 1 May 2014

      Covance ( CVD ): Q1 EPS of $0.90 beats by $0.01 . Revenue of $620.1M (+6.9% Y/Y) misses by $11.91M . Press Release Post your comment!

    5. Charles River Posts Solid 4Q as Preclinical Services Finally Rebound

      Commentary

      Thu, 13 Feb 2014

      growth since 2008. Management stated it is stealing market share from competitors, which we believe is accurate given that Covance reported just 5% revenue growth for its early-stage business in the fourth quarter.

    6. Covance 4Q Results Meet Expectations, Early-Stage Business Shows Signs of Improvement

      Commentary

      Wed, 5 Feb 2014

      Covance reported solid fourth-quarter results that ..... growth in the clinical development business. Covance ’s book-to-bill ratio held steady at ..... growth is sustainable over the near term. Covance was able to leverage the strong growth into

    7. Late-Stage Businesses Drive Narrow Moats for CROs

      Headlines

      Fri, 29 Nov 2013

      the CROs we cover: Quintiles Q, Covance CVD , Parexel PRXL, ICON ICLR, Charles ..... enrollment and drug development. Covance CVD estimates that more than 50 ..... development CROs we cover--Quintiles, Covance , ICON, and Parexel--fueled by

    8. Early-Stage Business Appears to be Bottoming as Covance Reports Strong Earnings Growth

      Commentary

      Wed, 30 Oct 2013

      Covance reported third-quarter results that met our ..... which bodes well for near-term growth. Covance ’s early-stage business appears to be ..... Charles River posted. On an adjusted basis, Covance ’s early-stage operating margin improved

    9. Charles River Posts Solid Earnings Growth Despite Ongoing Weakness in Early-Stage R&D Spending

      Commentary

      Wed, 30 Oct 2013

      growth this quarter, versus just 1% growth reported by Covance 's early-stage business. This outperformance has been ..... sales up 4.7% year to date, versus a 0.4% decline at Covance . Charles River's segment margin also increased slightly

    10. Pfizer Partnership Drives Margin Expansion in ICON's 3Q Results

      Commentary

      Thu, 24 Oct 2013

      operating margins, which would be in line with the margins currently posted by the late-stage businesses of competitors Covance and Quintiles. As a result of the strong quarter, management slightly raised its non-GAAP earnings per share guidance

    « Prev12345Next »
    Content Partners